Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2093867 Target Snapshot

Protein kinase C (PKC) · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
704Compounds
285Assays
3Approved Drugs
566.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein kinase C (PKC) shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O94806. Start with neoplasm, then reuse UniProt O94806 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt O94806 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
neoplasm

Protein kinase C (PKC) shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include MIDOSTAURIN, UCN-01. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein kinase C (PKC) as ChEMBL target CHEMBL2093867, mapped to UniProt O94806. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein kinase C (PKC)
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2093867
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O94806
Serine/threonine-protein kinase D3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Protein kinase C (PKC) is the right protein anchor across sources, using UniProt O94806 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameProtein kinase C (PKC)
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtO94806
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase D3
UniProt AccessionO94806
Component TypeProtein
Sequence Length890 aa

Serine/threonine-protein kinase D3

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Protein kinase C (PKC), mapped to UniProt O94806. ChEMBL maps the protein component as Serine/threonine-protein kinase D3. Sequence length is 890 aa.

Mapped IDO94806
Review nameProtein kinase C (PKC)
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Protein kinase C (PKC) shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
neoplasm
2 linked drugs · 2 direct · 2 efficacy
Linked drugMIDOSTAURIN
Linked drugUCN-01
Approved-linked Approved
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugMIDOSTAURIN
Approved-linked Approved
mast-cell leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugMIDOSTAURIN
Approved-linked Approved
Mastocytosis
1 linked drug · 1 direct · 1 efficacy
Linked drugMIDOSTAURIN
Approved-linked Approved
systemic mastocytosis
1 linked drug · 1 direct · 1 efficacy
Linked drugMIDOSTAURIN
Late clinical Phase III
leukemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugMIDOSTAURIN
Linked drugUCN-01
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include MIDOSTAURIN, UCN-01. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
3
Phase III
4
Phase II
Assay Mix

Activity Type Distribution

IC50528.0
KI14.0
EC5023.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 10.1 IC50 0.08 Preclinical
CHEMBL4442196 10.05 IC50 0.09 Preclinical
CHEMBL3741746 9.89 IC50 0.13 Preclinical
CHEMBL4575056 9.85 IC50 0.14 Preclinical
CHEMBL4528495 9.82 IC50 0.15 Preclinical
CHEMBL4538431 9.77 IC50 0.17 Preclinical
CHEMBL4443190 9.74 IC50 0.18 Preclinical
CHEMBL3741746 9.72 EC50 0.19 Preclinical
CHEMBL4435580 9.66 IC50 0.22 Preclinical
CHEMBL4587471 9.44 IC50 0.36 Preclinical
Distribution

pChEMBL Value Distribution

44
5.0
25
5.5
36
6.0
38
6.5
34
7.0
17
7.5
24
8.0
6
8.5
5
9.0
7
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
Properties Compare Identifier
INGENOL MEBUTATE
CHEMBL1863513
Approved 2010
Properties Compare Identifier
TAMOXIFEN
CHEMBL83
Approved 1977
Properties Compare Identifier
Assay Landscape

Assay Landscape

285
Total Assays
271
Tested Compounds
2
Assay Types
Binding — 277 assays, 271 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 112 214 6.0
cell-based format 85 26 7.0
assay format 80 31 6.2
Functional — 8 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 8 3 4.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine